SeerPharma has been a strategic partner of MasterControl, a market-leading software provider, for the past eight years in the APAC region. During this time, we have assisted nearly 100 pharmaceutical and medical device companies in automating their quality management and manufacturing workflows. This level of automation has enabled our clients to...
ISPE Pharma 4.0TM – is a trademark owned by the International Society for Pharmaceutical Engineering, Inc. and registered in multiple countries.
The International Society for Pharmaceutical Engineering (ISPE) is a global not-for-profit association dedicated to serving its members across the entire pharmaceutical product lifecycle. With affiliates...
SeerPharma is a strategic partner with market-leading software solution provider – MasterControl. Our partnership, over the last 7 years, has seen us deploy this solution to digitise Quality and Manufacturing workflows to over 85 companies across the APAC region. In that time, we have seen our clients utilise MasterControl to break down silos and...
2024 Pharmaceutical Industry Trends
MasterControl Webinar: Medical Device Quality & Manufacturing Trends
SeerPharma are strategic partners with market leading software solution provider – MasterControl. Our partnership, over the last 7 years, has seen us deploy this solution to digitise Quality and Manufacturing workflows to over 75 companies.
MasterControl is running a webinar on current industry trends facing Quality and Manufacturing professionals...
2024 Medical Device Industry Trends
Infographic: Performance Snapshot for 2023
INFOGRAPHIC: A snapshot of how SeerPharma supported its clients with Quality and GMP Best-Practices in 2023 through QA & GMP Consulting, Auditing, Training and MasterControl "Qx" electronic Quality Management Systems (eQMS) & "Mx" Manufacturing Execution Systems (MES) with electronic Batch Records (eBR).
2023 Medical Device Manufacturing Trends
If we could predict the future of the pharma manufacturing industry, we wouldn’t have been rattled by supply disruptions throughout the pandemic. And we would’ve been able to anticipate which products would unexpectedly experience weak demand. At the very least, we could’ve predicted which winning therapies to invest in! So why do we waste time...